BioFund Ventures · United States

Five platforms. One mission. The right collaborator gets access.

BioFund Ventures places real research assets — proteins, cell lines, processing capacity, and AI discovery tools — in the hands of researchers who share the mission of curing and preventing cancer.

Not a fund you pitch to. A platform you partner with.

Why BioFund Ventures

Cancer won't be solved in a single lab. The science is distributed. We spent years building the platforms — and we're now placing them where the work is actually happening.

BioFund is a family office founded by seven families with one mission: to cure and prevent cancer. We work through a OneHealth approach — companion animals as the first clinical validation pathway, human therapeutics as the destination, and prevention through bioactive science as the other half of the equation. BioFund Ventures is our US operating entity. For years, we built and refined five research platforms for our own science. We are now opening them to mission-aligned collaborators across the United States — selectively, through relationships, one real project at a time.

What we bring to a collaboration

We invest our platforms where the science is real.

Five platforms built for our own research. Each collaboration begins with one — the specific one that fits your program. Not a menu, a match. Everything below was built for our own science. The right partner gets access.

01

Novel proteins & biosimilars

We produce novel proteins and biosimilars for our own oncology and OneHealth research, held in a growing Master Cell Bank. When a research program needs a protein we already carry, access comes through a joint project — no lengthy procurement, no ambiguous IP terms.

What you get

Research-grade access to specific proteins from our Master Cell Bank through a jointly structured project. Your IP stays yours. Publications by mutual agreement.

In practice A research team needed a specific reference protein to advance their oncology work. We had produced it for our own use. We opened access through a joint project. Their work moved forward.
02

Cell line engineering

When a researcher has a promising molecule and the biology is fighting back — unstable expression, insufficient yield — we engineer a stable, high-yield cell line around their molecule. The discovery is entirely theirs. We solve the biology problem that was blocking it.

What you get

A stable, high-yield, production-ready cell line engineered around your molecule. You own the cell line and everything derived from it.

In practice A researcher had a molecule with real therapeutic potential — it wouldn't express at the yield the work demanded. We built a stable cell line around it. The science that had been stalling began to move.
03

Animal health & OneHealth

Companion animals develop the same cancers humans do — spontaneously, in real bodies, on real timelines. We work with veterinary researchers whose patients need care today. The data those studies generate shortens the road to human therapeutics. One act of medicine, two beneficiaries.

What you get

A translational oncology partner for companion animal studies. Data structured from day one to inform human therapeutic development. Shared rights by agreement.

In practice Our lead therapeutic asset is entering companion animal trials first — generating real-world clinical data in a fraction of the time a conventional human-first pathway would require, while helping animals that need treatment now.
04

UFP500 platform

We built the UFP500 platform for our own prevention research — ultra-fine particle processing that transforms plant, marine, and agricultural material into research-grade ingredients with documented bioavailability enhancement. If your research involves a material that deserves a better delivery form, we process it.

What you get

A UFP500 processing run of your material, with full analytical documentation of particle size and bioavailability characteristics. Your material, your data, your IP.

In practice A seafood processor was discarding lobster shell — rich in bioactive compounds, headed for landfill. Run through UFP500, it became a validated research ingredient. Prevention and zero-waste, in one project.
05

AI-guided bioactive discovery

We built micronutri.ai for our own search for compounds that protect cells before disease takes hold. Curing cancer is one half of the mission. The other half is making sure fewer people need to be cured. If you have a discovery problem where that intelligence layer helps, we work on it with you.

What you get

Access to the micronutri.ai platform for a jointly scoped bioactive research project, structured around your specific compound or target. IP on discoveries stays with the originating researcher.

In practice micronutri.ai grew from our own prevention research — mapping the bioactive landscape to find what the science predicts will matter. The platform is open to partners whose work shares that upstream ambition.
06

Your collaboration
begins here.

The network is open.

We are an impact investor, not a donor: we commit our platforms first, and look to build toward shared investment as a collaboration proves itself.

How we work

Direct. Fast. Real.

i

We meet

Through a warm introduction or a direct reach-out to our San Francisco team. The first conversation is a conversation — what you're working on, what's blocking it, whether there's a fit. We know quickly when it's there, and we say so when it isn't.

ii

We find the fit

One platform, matched to one specific problem in your program. Not a menu — the specific protein, the processing run, the cell line, the AI pilot. If the fit isn't obvious, we say so and don't waste your time.

iii

We commit first

We ship the protein, run the processing, or stand up the AI pilot — before we negotiate terms. That's how we prove we're serious. As the work proves itself, we look to build toward shared investment on both sides. We are not a grant program.

iv

We grow the network

Good work earns introductions. The collaborator who joined through a trusted connection becomes the reference for the next one. That's how this network grows — the same way every real research relationship does. Through people who can say, from direct experience, that the work was genuine.

The ecosystem behind every collaboration

When you work with one part of BioFund, you meet all of it.

A single collaboration opens onto the wider world of the mission — each entity a doorway to the others.

biofund.org biodeep.ai micronutri.ai BioFund Ventures BioFund Animal Health NORI m-Institute UFP500

Explore the whole ecosystem at universe.biofund.org.

If your research shares the mission, there is a platform for your work in the Alliance.

Start a conversation Tell us what you're working on and where you think there's a fit. We always respond where alignment is real.